The complaint filed against the animal health company centers on claims that leadership obscured a decline in the performance of key products. Specifically, the lawsuit alleges that the company failed to disclose that veterinarian adoption of the canine pain treatment Librela faltered following FDA safety warnings regarding neurological complications in treated dogs.

Beyond Librela, the suit contends that Zoetis lost critical market share for its Simparica Trio to lower-priced competitors and faced new rivalry for its dermatology blockbusters, Apoquel and Cytopoint. According to the court filing, these undisclosed pressures rendered the company’s public statements about its business operations and growth prospects materially misleading. Investors seeking to participate in the case or discuss their legal standing may contact the Law Offices of Howard G. Smith in Bensalem, Pennsylvania, before the late-July deadline.